Promising Drug Could Be Game Changer for Pulmonary Fibrosis
Philadelphia, PA – A new investigational drug that could be a game changer in the treatment of idiopathic pulmonary fibrosis (IPF) is being offered to patients at Temple Lung Center as part of a limited “expanded access” program in advance of the drug’s regulatory approval.
Results of a recently published phase III trial showed that the drug, pirfenidone, slowed disease progression in patients with IPF, a debilitating and deadly lung condition. The need for new therapies for IPF is critical, given that the condition is irreversible and median time of survival for patients is two years from the time of diagnosis.
“Previously there wasn't evidence for effective drug therapy in patients with IPF ,” said Gerard J. Criner, MD, Professor of Medicine at Temple University School of Medicine, and Director of the Temple Lung Center, a recognized national leader in clinical care and research for lung disease.
The disease is usually of unknown origin — thus the name “idiopathic” pulmonary fibrosis. According to the American Lung Association, about 140,000 Americans have the disease, which most commonly affects persons between the ages of 50 to 75.
“A better understanding of biology of IPF and the pathways involved in the disease has led to the development of new drug targets,” said Dr. Criner, who is also Director of Pulmonary and Critical Care Medicine at Temple University Hospital. Continue>
Posted in: News Briefs | March 19, 2014
Posted in: News Briefs | November 8, 2013